Study of SRP-4045 and SRP-4053 in Participants With Duchenne Muscular Dystrophy (DMD)
Recruiting
Sarepta Therapeutics
Phase 3
2016-09-28
The main objective of this study is to evaluate the efficacy of SRP-4045 and SRP-4053
compared to placebo in participants with DMD with out-of-frame deletion mutations amenable to
skipping exon 45 and exon 53, respectively.
Study of SRP-4045 and SRP-4053 in Participants With Duchenne Muscular Dystrophy (DMD)
Recruiting
Sarepta Therapeutics, Inc.
Phase 3
2016-09-28
The main objective of this study is to evaluate the efficacy of SRP-4045 and SRP-4053
compared to placebo in participants with DMD with out-of-frame deletion mutations amenable to
skipping exon 45 and exon 53, respectively.
An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy
Enrolling by invitation
Sarepta Therapeutics
Phase 3
2018-08-02
The main objective of this study is to evaluate the safety and tolerability of long-term
treatment with casimersen or golodirsen in patients with Duchenne muscular dystrophy (DMD).
An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy
Enrolling by invitation
Sarepta Therapeutics, Inc.
Phase 3
2018-08-02
The main objective of this study is to evaluate the safety and tolerability of long-term
treatment with casimersen or golodirsen in patients with Duchenne muscular dystrophy (DMD).
A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of Casimersen, Eteplirsen and Golodirsen in Subjects With Duchenne Muscular Dystrophy Carrying Eligible DMD Duplications
Active, not recruiting
Sarepta Therapeutics, Inc.
Phase 2
2020-02-18
This is an 48-week open-label study to determine the efficacy and safety of casimersen,
eteplirsen, or golodirsen for the treatment of boys with duchenne muscular dystrophy who have
a single exon duplication of either exon 45, 51 or 53, respectively. There will be weekly
infusions and two muscle biopsies at baseline and at month 12.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
